Inicio>>Signaling Pathways>> DNA Damage/DNA Repair>> CDK>>hSMG-1 inhibitor 11j

hSMG-1 inhibitor 11j

Catalog No.GC61925

El inhibidor 11j de hSMG-1, un derivado de la pirimidina, es un inhibidor potente y selectivo de hSMG-1, con una IC50 de 0,11 nM. El inhibidor de hSMG-1 11j muestra una selectividad de >455 veces para hSMG-1 sobre mTOR (IC50 = 50 nM), PI3Kα/γ (IC50 = 92/60 nM) y CDK1/CDK2 (IC50 = 32/7,1 μM). El inhibidor de hSMG-1 11j se puede utilizar para la investigaciÓn del cÁncer.

Products are for research use only. Not for human use. We do not sell to patients.

hSMG-1 inhibitor 11j Chemical Structure

Cas No.: 1402452-15-6

Tamaño Precio Disponibilidad Cantidad
5 mg
450,00 $
Disponible
10 mg
765,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

hSMG-1 inhibitor 11j, a pyrimidine derivative, is a potent and selective inhibitor of hSMG-1, with an IC50 of 0.11 nM. hSMG-1 inhibitor 11j exhibits >455-fold selectivity for hSMG-1 over mTOR (IC50=50 nM), PI3Kα/γ (IC50=92/60 nM) and CDK1/CDK2 (IC50=32/7.1 µM). hSMG-1 inhibitor 11j can be used for the research of cancer[1].

hSMG-1 inhibitor 11j (0.3-3 µM; 6 h) significantly reduces UPF1 phosphorylation at 0.3 µM, and eliminates it at 1 µM in MDA 361 cells[1].hSMG-1 inhibitor 11j inhibits MDA468 cell proliferation, with an IC50 of 75 nM[1].

References:
[1]. Gopalsamy A, et, al. Identification of pyrimidine derivatives as hSMG-1 inhibitors. Bioorg Med Chem Lett. 2012 Nov 1;22(21):6636-41.

Reseñas

Review for hSMG-1 inhibitor 11j

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for hSMG-1 inhibitor 11j

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.